News
- Author:
- Jim Kling
Publish date: November 8, 2017
A cure at 6 months could be accurately predicted with a 50% reduction in PTH levels during surgery, concordant imaging, and single-gland disease.
News
- Author:
- Jim Kling
Publish date: November 3, 2017
SAN DIEGO – A small study showed that levels of tau protein and amyloid-beta in the cerebrospinal fluid correlated with postmortem findings of Alzh...
News
- Author:
- Jim Kling
Publish date: November 1, 2017
These devices have the potential to disseminate undetected tumor tissue.
News
- Author:
- Jim Kling
Publish date: November 1, 2017
CULPRIT-SHOCK shows advantages of leaving nonculprit lesions alone.
Video
- Author:
- Jim Kling
Publish date: November 1, 2017
SAN DIEGO – Further refinements to a smartphone EEG system could bring diagnostic capabilities to poor and underserved areas of the world.
News
- Author:
- Jim Kling
Publish date: October 30, 2017
Commercial insurers are the least likely to pay for the new cholesterol-lowering drugs.
News
- Author:
- Jim Kling
Publish date: October 27, 2017
SAN DIEGO – Solriamfetol improved sleepiness scores, compared with placebo, and may have a low addiction risk.
News
- Author:
- Jim Kling
Publish date: October 26, 2017
SAN DIEGO – Twelve months after a stroke, Mexican Americans performed worse on a cognitive function battery than did non-Hispanic whites.
Video
- Author:
- Jim Kling
Publish date: October 19, 2017
Results from the DAWN and DEFUSE 3 trials show that some patients with ischemic stroke can benefit from treatment even out to 24 hours.
Video
- Author:
- Jim Kling
Publish date: October 17, 2017
Mobile stroke units can deliver stroke diagnosis and treatment, circumventing the transportation time to the emergency department. But are they cos...
News
- Author:
- Jim Kling
Publish date: October 16, 2017
An analysis of rehospitalization shows associations with blood sugar problems and dyslipidemia, but not hypertension or smoking.
Video
- Author:
- Jim Kling
Publish date: October 16, 2017
Positive long-term, open-label trial results are prompting investigators to think how they might adapt approaches to future research.
News
- Author:
- Jim Kling
Publish date: October 15, 2017
The mTOR inhibitor is the first antiepilepsy drug to be selected for its mechanism of action.
News
- Author:
- Jim Kling
Publish date: October 9, 2017
A decline in the diagnosis and treatment of osteoporosis has experts worried about a new epidemic of fractures. Fracture liaison services and initi...
News
- Author:
- Jim Kling
Publish date: October 6, 2017
Dr. Joseph Fowler reviews existing and newer medications available for treating eczema that does not respond to topical agents.
